HCA Healthcare, Inc. (HCA) stock analysis
Close on Nov 11, 2026Market cap $105.71BP/E 16.8Yield 0.57%
StockData Score
Prices as of Nov 11, 2026How the score works
Mixed9 of 30 checks passed
HCA Healthcare passes 9 of the 30 checks behind our score; 7 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 1/6
- Growth
- 2/6
- Past performance
- 2/6
- Financial health
- 1/6
- Dividend
- 3/6
What stands out
Earnings grew over 5 years
Net income grew 12.6% a year on average over the last five fiscal years.
EPS growing 10%+ a year
Diluted EPS grew 13.9% a year over the last three fiscal years.
Debt covered by cash flow
Operating cash flow over the last twelve months equals 22.1% of total debt.
P/E below the industry
HCA Healthcare's P/E of 16.8 is below the Health Services median of 23.9.
What to watch
Margin of safety under 20%
The price is 2.2% above fair value, so there is no margin of safety.
Trading above fair value
The share price of $506.04 is above our fair value estimate of $495.17.
Revenue growing under 10% a year
Revenue grew 7.9% a year over the last three fiscal years, short of the 10% we look for.
Earnings growth not accelerating
Net income grew 6.8% over the last twelve months, against a 5-year average of 12.6% a year.
Valuation1/6
P/E above its 5-year median
HCA Healthcare's P/E of 16.8 is above its own 5-year median of 14.4.
P/E below the industry
HCA Healthcare's P/E of 16.8 is below the Health Services median of 23.9.
EV/EBITDA above its 5-year median
HCA Healthcare's EV/EBITDA of 10.0 is above its 5-year median of 9.0.
P/S above the industry
HCA Healthcare's price-to-sales of 1.34 is above the Health Services median of 1.05 (book value is negative, so we use sales).
Trading above fair value
The share price of $506.04 is above our fair value estimate of $495.17.
Margin of safety under 20%
The price is 2.2% above fair value, so there is no margin of safety.
Growth2/6
Revenue growing under 10% a year
Revenue grew 7.9% a year over the last three fiscal years, short of the 10% we look for.
EPS growing 10%+ a year
Diluted EPS grew 13.9% a year over the last three fiscal years.
Earnings growth not accelerating
Net income grew 6.8% over the last twelve months, against a 5-year average of 12.6% a year.
Growing faster than the industry
Revenue grew 5.8% over the last twelve months; the Health Services median is 4.0%.
Guidance lowered
HCA Healthcare lowered its 2026 EPS (diluted) outlook on Jul 14, 2026.
Gross margin trend
This company does not report gross profit.
Past performance2/6
Return on equity
Needs positive equity and five years of results.
Return on invested capital
Needs operating income and invested capital.
Return on equity against the industry
Needs positive equity.
Earnings grew over 5 years
Net income grew 12.6% a year on average over the last five fiscal years.
Net margin below its 5-year average
Net margin was 8.6% over the last twelve months, against a 5-year average of 9.3%.
Net margin above the industry
HCA Healthcare's net margin of 8.6% is above the Health Services median of -2.6%.
Financial health1/6
Debt level
Needs debt and equity figures.
Debt trend
Needs a balance sheet from five years ago with positive equity.
Debt covered by cash flow
Operating cash flow over the last twelve months equals 22.1% of total debt.
Interest coverage
Interest expense is not reported separately.
Short-term assets don't cover short-term debts
Current assets are 0.82 times current liabilities.
Bankruptcy risk in the grey zone
The Altman Z-score is 1.93; above 3 is the safe zone and below 1.8 the distress zone.
Dividend3/6
Pays a dividend
HCA Healthcare paid dividends worth 0.6% of the share price over the last twelve months.
Yield below Treasuries
The 0.6% yield is below the 4.4% on a 1-year Treasury.
Yield below the top quarter
The top quarter of US dividend payers yield 3.8% or more; HCA Healthcare yields 0.6%.
Dividend was cut
The dividend per share fell by more than 10% at least once in the last 8 fiscal years.
Covered by earnings
Dividends take 10.1% of net income.
Covered by free cash flow
Dividends take 11.4% of free cash flow.
Fair value
How we estimate itOur estimate per share
$495.17
The share price is 2% above this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| P/E | 19.1× | 14.4× | 23.9× | $577.12 | 44% |
| EV/EBITDA | 8.8× | 9.0× | 8.6× | $431.78 | 39% |
| Earnings power | 8.5% cost of equity | – | – | $424.54 | 17% |
| Fair value | $495.17 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/E at month end
- Own 5-year median 14.4
- Health Services median 23.9
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Low risk
- Average value traded per day
- $623.01M
- Value traded per 1% price move
- $424.06M
Downside
Medium risk
- Typical loss in a bad month
- 15.3%
- Volatility (annualized)
- 33%
- Sharpe ratio, 1 year
- 0.18
- Beta to the S&P 500 (5Y)
- 0.73
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2011 to 2025
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +7.1% | +7.9% | +8.0% | – | |
| Net income | +17.8% | +6.3% | +12.6% | +12.3% | |
| EPS, diluted | +28.8% | +13.9% | +21.0% | +19.0% | |
| Free cash flow | +36.4% | +23.1% | +3.8% | +12.5% | |
| Dividend per share | +9.1% | +8.7% | +46.3% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -38.8% | -335.8% | -159.1% | |
| Return on assets | 8.7% | 8.1% | 11.3% | |
| Current ratio | 1.56 | 1.42 | 0.97 | |
| Debt to equity | -4.30 | 54.20 | -7.71 | |
| Capex to revenue | 6.7% | 5.5% | 6.5% | |
| Diluted shares | 396M | 344M | 239M |
Where the cash went
Fiscal 2021 to 2025, five years combined
HCA Healthcare generated $50.06B from operations and spent $60.98B on capital expenditure, dividends and share buybacks. 37% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 9.0% | 1.26× | -14.10× | -159.1% |
| FY2024 | 8.2% | 1.22× | -27.08× | -269.6% |
| FY2023 | 8.1% | 1.20× | -23.93× | -230.9% |
| FY2022 | 9.4% | 1.17× | -27.89× | -305.0% |
| FY2021 | 11.8% | 1.20× | -272.11× | -3853.7% |
| FY2020 | 7.3% | 1.11× | -41.39× | -335.8% |
| FY2019 | 6.8% | 1.22× | -10.86× | -90.4% |
| FY2018 | 8.1% | 1.23× | -6.45× | -64.4% |
| FY2017 | 5.1% | 1.24× | -4.99× | -31.4% |
| FY2016 | 7.0% | 1.25× | -4.46× | -38.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$6.78B
- Cash generatingOperating cash flow above zero$12.64B
- Return on assets improvedROA up on the prior year10.2% → 11.4%
- Earnings backed by cashOperating cash flow above net income$12.64B vs $6.78B
- Less leverageLong-term debt to assets fell64.4% → 68.5%
- Better liquidityCurrent ratio rose1.08 → 0.97
- No dilutionShare count did not rise262M → 239M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose1.26 → 1.27
See a number that looks wrong?